Kurzfassung

B1181003: A phase II multi-center, randomized, double-masked, placebo-controlled, multi-dose study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of RN6G (PF-04382923) in subjects with geograhpic atrophy secondary to age-related macular degeneration